Member Info for David1951c

THX is producing stellar results and compares favourably to all other gold miners on AIM and it pays a dividend. Q2 2025 net profit of US$51.6 million (Q2 2024: US$33.7 million) and H1 2025 of US$86.1 million (H1 2024: US$39.9 million).

· Net cash of US$52.8 million as at June 30, 2025.

H2 could produce a net profit of $100m and 2025 could approach £200m. They can easily afford the different drilling programmes and fund Douta production if DFS favourable. Key issue remains LoM extension at Segilola to support the transition to mid tier miner status.

THX are the lowest in H1 with $915; ACG $1060; PAF $1525; SRB $1762. THX should be the most profitable relative to size and actual FY profit highly significant.

H1 Results should be announced by the end of September together with an operational update. With higher gold prices and lower AISC the margin is approaching $2k per oz. This will improve in Q3. A very profitable period which will support the expansion. The AISC is one of the lowest on AIM; much better than PAF and nearly as good as THX.

At this stage the money side of the deal is not significant for Apta. If Metir are successful then the contract value will rise. More important is showing that it works well and the Apta involvement is a key factor. It is the breadth of Apta applications that is remarkable.

The test reported on by BBC is a blood test so a saliva based test would be much easier to carry out and less intrusive. Neuro Bio are aiming to complete and validate the saliva test in 18 months so should not be too far behind. The other comparison is accuracy and the blood test is said to be 90% accurate.

Neuro Bio are collaborating with a number of universtities so should have the resources to deliver the test in an effective and timely manner.

THX continues to be one of the best prospective mining stocks. It has amongst the lowest costs (AISC) of any gold miner and is the most profitable one on AIM. There are numerous reasons for the SP to rise materially in Q4 with some exciting catalysts:

1. Operational update for Q3 in mid October;

2. Financial results for Q3 in mid November;

3. News on mine life extension for Segilola;

4. PFS for Douta;

5. Other drilling updates.

The cash generation at current PoG will be significant and hopefully finance further extensive drilling with may be a rise in dividend.

There is not another producing miner on AIM which is better placed IMO.

Next RNS is likely to be interim results towards the end of the month which may help support current SP. The big catalyst will be 2026 production guidance likely to be over 16k BOED and possibly more with additional wells coming on stream. In December the tax rebate on Balder should be received . About €65m which should mean company is well cashed up. Have faith in AA to deliver.

Given the higher PoG the sell off is surprising. Possibly some investors see more immediate gains possible in other mining stocks such as OMI. However THX is still a great one to hold with amongst the lowest AISC and highest profits of any quoted gold miner. With lots of news to come in Q4 it is only a minor fall back.

I think Apta would still be able to announce licencing and other agreements and major developments as they actually complete and sign. With the company having a significant pipeline, a relatively small share purchase like this one would not be precluded. At this point in time we all know some deals are close to completion but exactly what and when depends on progress with negotiations and finalisation of agreements for signing.

Bought in this morning 100k @ 8.75. Prospects look good and only concern is cash runway as H2 26 is not that far away in financing terms. Companies needing funds cannot leave it too long. Given Scancell's progress it should be posible to get funding without equity dilution.

There are a number of bios in a similar position including Apta, FAB, Shield, SVNS, TCF and others. SPs are low and provide great entry points with important milestones coming up in next 3/4 months. Have holdings in all as difficult to decide which has best prospects.

For a while I believe AIM pricing is too volatile and wild share price swings happen too easily, which implies that it is capable of manipulation. Very frustrating to see such a large drop so quickly almost a reverse of the rise in the few weeks prior. Not wholly unexpected as I have quite a few AIM holdings and see this scenario too often..

I firmly believe Apta will become a significant company in the biopharma world due to their diverse and effective capabilities and will be taken over at some point. They work with so many majors that they must be on the radar. So SP drop feels painful it is only short term. A 1m buy @ 0.93 will appear as I topped up.

Given Apta are already working with the top 10 biopharmas and much of what they offer is non-exclusive to the customer, it should be possible for multiple deals with any or all. The biomarker service is only just starting and has great potential. There are other agreements with smaller biopharmas including Invizius, NeuroBio (Alzeimers Test) and Glasgow University. It is this breadth that underlines the potential and gives confidence in further growth.

Needs another plug by Midas to spread the word.

Hope it doesn't drop that far but given the volatility typical of AIM no-one knows for sure. I will buy another 1m if it does. I firmly believe that Apta will go much higher but with ups and downs on the way. Regular positive news flow will help and with multiple licensing deals expected that should be possible.

Means sp drifting down again. Do not expect a running commentary but with so much going on as outlined on 12 June a further update would be good practice in shareholder communication. People at Haydale may have made sacrifices but some shareholders have supported the company through thick and thin and have lost much of their investment.

Looking at the crude volume of buys v sells, perhaps there is a large sell being worked on. With so much in the pipeline and potential it seems hard to understand but on AIM a drop often happens on news.

Hi Imperial London,

Thanks for your further comments. It is a big endorsement for Apta from Invizius as it follows a detailed analysis confirming Apta are a leader in this field.

With such a broad spectrum of application, Apta must be on the radar of the majors. DC

Thanks for your views as always. Will the replacement of the protein binders mean thet phase 1 will need to be re-run? Clearly Invizius believe the optimer use has material advantages and they must have looked at revised timescales. If phase 2 can be carried out without too much delay then they be fairly certain. Would they be able to do phase 2 with both to enable a specific comparison?

Looking back at other developments, it is interesting to re-read 30 April RNS about optimers in vaccine adjuvants, which seems to offer a lot of promise for a successful development in a shorter timescale as it is for animal vaccine. However the wider application has significant potential especially if the animal vaccine is successfully introduced within 12 months.

I have no scientific knowledge but the meaning of adjuvant is interesting. In pharmacology, an adjuvant is a drug or other substance, or a combination of substances, that is used to increase the efficacy or potency of certain drugs. Specifically, the term can refer to: Adjuvant therapy in cancer management. Analgesic adjuvant in pain management. Immunologic adjuvant in vaccines.

Sorry to see a further decline in SP today. Not sure why this is happening other than typically a sustained selling of even small numbers of shares causes a much bigger SP drop than is justified. It would be good to know what's begind the selling. Too often is seems to relate to concerns about funding and this is a perennial problem form small biotechs (and other sectors) especially over the last four years. Lack of financial support from capital markets does leave companies exposed to heavy diluting equity fund raises and some companies go under e.g. Destiny Pharma which cost me quite a bit. More support for small listed companies with good potential would ideally be available but rarely happens.

I suspect one of the concerns from some retail investors on SVNS is whether more funds will need to be raised and lead to further dilution. Always a difficult and unpopular question but a concern for me. I would like to add but not sure of the timing.

There are a few other companies in the same boat as SVNS including Apta, FAB and TCF, all of which I hold. Shield and Apta have had a better run recently and SPs have increased considerably. It may be some sellers are moving to companies with more immediate SP potential and with momentum.

Now a 6m buy!

The Board have treated shareholders appallingly all the way through. Latest failure is to get the audit completed and accounts signed off. Communication has been dreadful and even now no indication of the remaining issues (why is it taking so long), the date accounts will be completed and suspension lifted.

It may be incompetence but treatment borders on criminal and directors should face an investigation for their failings and lack of fitness.